The main secondary goal ( cardiovascular death , myocardial infarction , vascular stroke , hospitalisation for a heart failure or angina pectoris and myocardial revascularisation ) occurred in 12.8 % ( 1,059 ) patients treated with saxagliptin and in 12.4 % ( 1,034 ) patients treated with placebo .